What the research examined
Studies of PNC-27 investigated membrane-associated HDM-2 and cell injury in selected cancer cell lines. Experimental work included binding observations and viability measurements in leukemia models, helping test a proposed cellular mechanism.
How to interpret the findings
Killing cultured cancer cells is not evidence of treating cancer in people. Selectivity among the cell lines tested cannot establish whole-body safety, tumor delivery, or improved survival. These papers should remain identified as laboratory research.
Research literature
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
Proceedings of the National Academy of Sciences of the United States of America · 2010 · PMID 20080680 - Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
Anticancer research · 2020 · PMID 32878773
Links open the indexed paper records. Summaries are based on those records and their available abstracts, not a systematic review or a full-text appraisal of every study.